MHRA Guidance on Brexit Implementation and ABPI Response

On 6th August, the MHRA published guidance on what the Brexit implementation period means for the life science sector:

The document covers the following areas:

• Market access for medicines during the implementation period
• Licensing and packaging
• Batch release and testing
• UK regulatory role
• Other points regarding the transition into the implementation period – medicines
• Implementation plans for related EU legislation during the implementation period

The ABPI have responded to this document, and you can read the statement made by Dr Sheuli Porkess, Deputy Chief Scientific Officer for the ABPI, here:

We are delighted that Dr Porkess will be joining us again at this year’s PIPA Conference, where she will share any further updates on this subject with the conference delegates.